The goal of the partnership between Topcon and Pangaea is to “accelerate the application of Pangaea’s clinically validated AI ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.

Telangiectatic capillaries may have potential clinical relevance for diagnosis and treatment of diabetic macular edema.

In India, a significant portion of adults grapple with both thyroid disorders and diabetes, often unaware of their ...

Thanks to advancements in early detection and treatment options, it's possible to live a long and healthy life after being ...

An oral drug that improves vision in DME [diabetic macular edema]  would be a game changer because it would be more ...

Aim Retinal oxygen metabolism is thought to be affected in diabetic retinopathy. The aim of this study was to test whether retinal vessel oxygen saturation is different in patients with diabetic ...

Fear is a natural response when something threatens your vision—but it’s also a signal to act quickly. Some retinal ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine ...

Cardiovascular disease remains the leading cause of death in patients with diabetes. Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk factors leads to ...